While these markers offer insights into systemic inflammation and metabolic dysfunction, the MASLD criteria exclude CRP and HOMA-IR for broader applicability, focusing on universally recognized risk factors like obesity, type 2 diabetes, and dyslipidaemia. This evidence concerns the gene CRP and obesity disorder.